Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan Porter

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
BMJ (Clinical Research Ed.)|August 6, 2010
Symmetrical polyarthritis. Time for treatment targets in rheumatoid arthritisPaul Emery, , Maya H Buch, et al.
Scientific Reports|January 17, 2017
Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroupsStefan Siebert, Duncan Porter, Caron Paterson, et al.
RMD Open|January 4, 2023
JAK inhibitors disrupt T cell-induced proinflammatory macrophage activationMukanthu H Nyirenda, Jagtar Singh Nijjar, Marina Frleta-Gilchrist, et al.
Metabolites|June 14, 2020
Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage ActivationRónán Daly, Gavin Blackburn, Cameron Best, et al.
The Lancet. Rheumatology|October 4, 2021
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort studyJagtar S Nijjar, Fraser R Morton, Holger Bang, et al.
Annals of the Rheumatic Diseases|March 31, 2016
Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trialJames Dale, Anne Stirling, Ruiqi Zhang, et al.
Annals of the Rheumatic Diseases|December 14, 2012
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritisGerd R Burmester, Michael E Weinblatt, Iain B McInnes, et al.
Lancet (London, England)|May 21, 2016
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trialDuncan Porter, Jurgen van Melckebeke, James Dale, et al.
BMC Musculoskeletal Disorders|November 11, 2016
The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobankJames Dale, Caron Paterson, Ann Tierney, et al.
Arthritis Research & Therapy|May 9, 2025
Smoking as a risk factor for rheumatoid arthritis: predominant association with IgA autoantibodies - comprehensive analysis of anti-modified protein antibodies with smoking and genetic risk factors in rheumatoid arthritisTineke J van Wesemael, Fraser R Morton, Judith W Heutz, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
BMJ (Clinical Research Ed.)|August 6, 2010
Symmetrical polyarthritis. Time for treatment targets in rheumatoid arthritisPaul Emery, , Maya H Buch, et al.
Scientific Reports|January 17, 2017
Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroupsStefan Siebert, Duncan Porter, Caron Paterson, et al.
RMD Open|January 4, 2023
JAK inhibitors disrupt T cell-induced proinflammatory macrophage activationMukanthu H Nyirenda, Jagtar Singh Nijjar, Marina Frleta-Gilchrist, et al.
Metabolites|June 14, 2020
Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage ActivationRónán Daly, Gavin Blackburn, Cameron Best, et al.
The Lancet. Rheumatology|October 4, 2021
The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort studyJagtar S Nijjar, Fraser R Morton, Holger Bang, et al.
Annals of the Rheumatic Diseases|March 31, 2016
Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trialJames Dale, Anne Stirling, Ruiqi Zhang, et al.
Annals of the Rheumatic Diseases|December 14, 2012
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritisGerd R Burmester, Michael E Weinblatt, Iain B McInnes, et al.
Lancet (London, England)|May 21, 2016
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trialDuncan Porter, Jurgen van Melckebeke, James Dale, et al.
BMC Musculoskeletal Disorders|November 11, 2016
The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobankJames Dale, Caron Paterson, Ann Tierney, et al.
Arthritis Research & Therapy|May 9, 2025
Smoking as a risk factor for rheumatoid arthritis: predominant association with IgA autoantibodies - comprehensive analysis of anti-modified protein antibodies with smoking and genetic risk factors in rheumatoid arthritisTineke J van Wesemael, Fraser R Morton, Judith W Heutz, et al.
Pageof 4